Zacks Research Forecasts Qiagen's Q3 Earnings (NYSE:QGEN)

Qiagen (NYSE:QGEN - Free Report) - Analysts at Zacks Research decreased their Q3 2025 EPS estimates for Qiagen in a research note issued on Thursday, April 24th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.57 for the quarter, down from their prior estimate of $0.58. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%.

A number of other research analysts have also recently issued reports on the stock. UBS Group reduced their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Robert W. Baird lifted their price target on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Morgan Stanley reaffirmed an "equal weight" rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Finally, Baird R W lowered Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $48.42.

Qiagen Stock Up 2.4 %

NYSE QGEN traded up $1.00 during mid-day trading on Monday, hitting $43.20. The company's stock had a trading volume of 265,746 shares, compared to its average volume of 1,120,996. The firm has a market capitalization of $9.60 billion, a price-to-earnings ratio of 120.32, a PEG ratio of 2.39 and a beta of 0.62. The company's 50 day simple moving average is $40.21 and its 200 day simple moving average is $41.71. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Institutional Investors Weigh In On Qiagen

Large investors have recently made changes to their positions in the business. Groupama Asset Managment increased its holdings in Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after buying an additional 32,216,761 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after acquiring an additional 2,202,040 shares during the period. Wellington Management Group LLP grew its position in shares of Qiagen by 2.5% during the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock valued at $970,534,000 after acquiring an additional 531,362 shares during the period. Vanguard Group Inc. increased its stake in shares of Qiagen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after purchasing an additional 77,119 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Qiagen in the 4th quarter worth approximately $181,529,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.